CDK4 and neoplasm: It was reported that several outcomes could emerge following the administration of anti-angiogenic antibodies, which include tumor vascular normalization that leads to improved drug delivery, remodeling of the immunosuppressive environment through regulating TAMs, MDSCs and Tregs, and blockade of tumor-intrinsic pathways, such as MAPK, WNT–β-catenin, CDK4/6 and/or PI3K–PTEN signaling, that cause immune cell exclusion [5].